Wu Zunyou: Vaccines are difficult to prevent SARS-CoV-2

Reporter : Zheng Gusheng

Editor: Ming Xuan

Publisher : New Tang Dynasty Television

Ref : https://www.ntdtv.com/gb/2020/06/26/a102880387.html

Translation, editing : Gan Yung Chyan

                                 / KUCINTA SETIA

Image courtesy : Pixabay

The China Communist Party (CCP) is competing for the "First Vaccine Development" against SARS-CoV-2 (covi, in short). However, many recent studies have shown that the so-called vaccine development may have limited effects. A few days ago, senior CCP experts also admitted that it is very difficult to use vaccines to prevent and control covi.

On 26 June 2020, Wu Zunyou, the chief expert in epidemiology of the China CDC, told the party media, China Youth Daily, that there is no vaccine that can be done once and for all. The problem of vaccines is very complicated. With the deepening of the understanding of covi, people are no longer as optimistic as they were.

He mentioned two points. First, the previous acute respiratory syndrome (SARS), Middle East Respiratory Syndrome (MERS) and other viruses are all coronaviruses like covi but so far, no coronavirus has been vaccinated.

Second, the duration of immunity produced by human infection with the virus is unknown. The latest research finds that people who have been infected with the virus "after a few months, the antibody will drop, or even fall to undetectable."

Wu Zunyou said that when the human body is infected with covi, the immune system can naturally produce antibodies to protect itself, and the development of a vaccine is to imitate this natural immune process. "If the human body cannot develop immunity after natural infection, the vaccine we have developed will not be able to protect people."

Wu Zunyou said that the immunity of the human body to covi will soon disappear, which constitutes a "great challenge", requiring the government to "produce a large amount of vaccines, while requiring people to be vaccinated at all times."

He said that the vaccine is still the "most promising" epidemic prevention and control measure, which should be applied at the end of this year or early next year, but based on the conclusions of the current research, the vaccine may not be a human "immunization pass" to covi.

Recently, the research results released by the US and Chinese research teams have shown that a considerable number of people will not produce antibodies after they are infected with covi. Even if antibodies are produced, most people's immunity can only last for two or three months, or even shorter.